HIV  ||| S:0 E:4 ||| NNP
resistance  ||| S:4 E:15 ||| NN
to  ||| S:15 E:18 ||| TO
raltegravir  ||| S:18 E:30 ||| VB
Similar  ||| S:30 E:38 ||| JJ
to  ||| S:38 E:41 ||| TO
all  ||| S:41 E:45 ||| DT
antiretroviral  ||| S:45 E:60 ||| JJ
drugs ||| S:60 E:65 ||| NNS
,  ||| S:65 E:67 ||| ,
failure  ||| S:67 E:75 ||| NN
of  ||| S:75 E:78 ||| IN
raltegravir-based  ||| S:78 E:96 ||| JJ
treatment  ||| S:96 E:106 ||| NN
regimens  ||| S:106 E:115 ||| NN
to  ||| S:115 E:118 ||| TO
fully  ||| S:118 E:124 ||| RB
supress  ||| S:124 E:132 ||| JJ
HIV  ||| S:132 E:136 ||| NNP
replication  ||| S:136 E:148 ||| VBD
almost  ||| S:148 E:155 ||| RB
invariably  ||| S:155 E:166 ||| JJ
results  ||| S:166 E:174 ||| NNS
in  ||| S:174 E:177 ||| IN
emergence  ||| S:177 E:187 ||| NN
of  ||| S:187 E:190 ||| IN
HIV  ||| S:190 E:194 ||| NNP
resistance  ||| S:194 E:205 ||| NN
to  ||| S:205 E:208 ||| TO
this  ||| S:208 E:213 ||| DT
new  ||| S:213 E:217 ||| JJ
drug ||| S:217 E:221 ||| NN
.  ||| S:221 E:223 ||| .
HIV  ||| S:223 E:227 ||| NNP
resistance  ||| S:227 E:238 ||| NN
to  ||| S:238 E:241 ||| TO
raltegravir  ||| S:241 E:253 ||| NN
is  ||| S:253 E:256 ||| VBZ
the  ||| S:256 E:260 ||| DT
consequence  ||| S:260 E:272 ||| NN
of  ||| S:272 E:275 ||| IN
mutations  ||| S:275 E:285 ||| NNS
located  ||| S:285 E:293 ||| VBN
close  ||| S:293 E:299 ||| RB
to  ||| S:299 E:302 ||| TO
the  ||| S:302 E:306 ||| DT
integrase  ||| S:306 E:316 ||| JJ
active  ||| S:316 E:323 ||| JJ
site ||| S:323 E:327 ||| NN
,  ||| S:327 E:329 ||| ,
which  ||| S:329 E:335 ||| WDT
can  ||| S:335 E:339 ||| MD
be  ||| S:339 E:342 ||| VB
divided  ||| S:342 E:350 ||| VBN
into  ||| S:350 E:355 ||| IN
three  ||| S:355 E:361 ||| CD
main  ||| S:361 E:366 ||| JJ
evolutionary  ||| S:366 E:379 ||| JJ
pathways ||| S:379 E:387 ||| NN
:  ||| S:387 E:389 ||| :
the  ||| S:389 E:393 ||| DT
N155H ||| S:393 E:398 ||| NNP
,  ||| S:398 E:400 ||| ,
the  ||| S:400 E:404 ||| DT
Q148R ||| S:404 E:409 ||| NNP
/ ||| S:409 E:410 ||| NNP
H ||| S:410 E:411 ||| NNP
/ ||| S:411 E:412 ||| NNP
K  ||| S:412 E:414 ||| NNP
and  ||| S:414 E:418 ||| CC
the  ||| S:418 E:422 ||| DT
Y143R ||| S:422 E:427 ||| NNP
/ ||| S:427 E:428 ||| NNP
C  ||| S:428 E:430 ||| NNP
pathways ||| S:430 E:438 ||| NN
.  ||| S:438 E:440 ||| .
Each  ||| S:440 E:445 ||| DT
of  ||| S:445 E:448 ||| IN
these  ||| S:448 E:454 ||| DT
primary  ||| S:454 E:462 ||| JJ
mutations  ||| S:462 E:472 ||| NNS
can  ||| S:472 E:476 ||| MD
be  ||| S:476 E:479 ||| VB
accompanied  ||| S:479 E:491 ||| VBN
by  ||| S:491 E:494 ||| IN
a  ||| S:494 E:496 ||| DT
variety  ||| S:496 E:504 ||| NN
of  ||| S:504 E:507 ||| IN
secondary  ||| S:507 E:517 ||| JJ
mutations  ||| S:517 E:527 ||| NNS
that  ||| S:527 E:532 ||| IN
both  ||| S:532 E:537 ||| DT
increase  ||| S:537 E:546 ||| NN
resistance  ||| S:546 E:557 ||| NN
and  ||| S:557 E:561 ||| CC
compensate  ||| S:561 E:572 ||| VB
for  ||| S:572 E:576 ||| IN
the  ||| S:576 E:580 ||| DT
variable  ||| S:580 E:589 ||| JJ
loss  ||| S:589 E:594 ||| NN
of  ||| S:594 E:597 ||| IN
viral  ||| S:597 E:603 ||| JJ
replicative  ||| S:603 E:615 ||| JJ
capacity  ||| S:615 E:624 ||| NN
that  ||| S:624 E:629 ||| WDT
is  ||| S:629 E:632 ||| VBZ
often  ||| S:632 E:638 ||| RB
associated  ||| S:638 E:649 ||| VBN
with  ||| S:649 E:654 ||| IN
primary  ||| S:654 E:662 ||| JJ
resistance  ||| S:662 E:673 ||| NN
mutations ||| S:673 E:682 ||| NNS
.  ||| S:682 E:684 ||| .
One  ||| S:684 E:688 ||| CD
unique  ||| S:688 E:695 ||| JJ
property  ||| S:695 E:704 ||| NN
of  ||| S:704 E:707 ||| IN
HIV  ||| S:707 E:711 ||| NNP
resistance  ||| S:711 E:722 ||| NN
to  ||| S:722 E:725 ||| TO
raltegravir  ||| S:725 E:737 ||| NN
is  ||| S:737 E:740 ||| VBZ
that  ||| S:740 E:745 ||| IN
each  ||| S:745 E:750 ||| DT
of  ||| S:750 E:753 ||| IN
these  ||| S:753 E:759 ||| DT
different  ||| S:759 E:769 ||| JJ
resistance  ||| S:769 E:780 ||| NN
pathways  ||| S:780 E:789 ||| NNS
are  ||| S:789 E:793 ||| VBP
mutually  ||| S:793 E:802 ||| RB
exclusive  ||| S:802 E:812 ||| JJ
and  ||| S:812 E:816 ||| CC
appear  ||| S:816 E:823 ||| VB
to  ||| S:823 E:826 ||| TO
evolve  ||| S:826 E:833 ||| VB
separately  ||| S:833 E:844 ||| RB
on  ||| S:844 E:847 ||| IN
distinct  ||| S:847 E:856 ||| JJ
viral  ||| S:856 E:862 ||| JJ
genomes ||| S:862 E:869 ||| NN
.  ||| S:869 E:871 ||| .
Resistance  ||| S:871 E:882 ||| NN
is  ||| S:882 E:885 ||| VBZ
frequently  ||| S:885 E:896 ||| RB
initiated  ||| S:896 E:906 ||| VBN
by  ||| S:906 E:909 ||| IN
viruses  ||| S:909 E:917 ||| NNS
carrying  ||| S:917 E:926 ||| VBG
mutations  ||| S:926 E:936 ||| NNS
of  ||| S:936 E:939 ||| IN
the  ||| S:939 E:943 ||| DT
N155H  ||| S:943 E:949 ||| JJ
pathway ||| S:949 E:956 ||| NN
,  ||| S:956 E:958 ||| ,
followed  ||| S:958 E:967 ||| VBN
by  ||| S:967 E:970 ||| IN
emergence  ||| S:970 E:980 ||| NN
and  ||| S:980 E:984 ||| CC
further  ||| S:984 E:992 ||| JJ
dominance  ||| S:992 E:1002 ||| NN
of  ||| S:1002 E:1005 ||| IN
viral  ||| S:1005 E:1011 ||| JJ
genomes  ||| S:1011 E:1019 ||| NNS
carrying  ||| S:1019 E:1028 ||| VBG
mutations  ||| S:1028 E:1038 ||| NNS
of  ||| S:1038 E:1041 ||| IN
the  ||| S:1041 E:1045 ||| DT
Q148R ||| S:1045 E:1050 ||| NNP
/ ||| S:1050 E:1051 ||| NNP
H ||| S:1051 E:1052 ||| NNP
/ ||| S:1052 E:1053 ||| NNP
K  ||| S:1053 E:1055 ||| NNP
or  ||| S:1055 E:1058 ||| CC
of  ||| S:1058 E:1061 ||| IN
the  ||| S:1061 E:1065 ||| DT
Y143R ||| S:1065 E:1070 ||| NNP
/ ||| S:1070 E:1071 ||| NNP
C  ||| S:1071 E:1073 ||| NNP
pathways ||| S:1073 E:1081 ||| NN
,  ||| S:1081 E:1083 ||| ,
which  ||| S:1083 E:1089 ||| WDT
express  ||| S:1089 E:1097 ||| VBP
higher  ||| S:1097 E:1104 ||| JJR
levels  ||| S:1104 E:1111 ||| NNS
of  ||| S:1111 E:1114 ||| IN
resistance ||| S:1114 E:1124 ||| NN
.  ||| S:1124 E:1126 ||| .
Even  ||| S:1126 E:1131 ||| RB
if  ||| S:1131 E:1134 ||| IN
some  ||| S:1134 E:1139 ||| DT
natural  ||| S:1139 E:1147 ||| JJ
integrase  ||| S:1147 E:1157 ||| JJ
polymorphisms  ||| S:1157 E:1171 ||| NN
can  ||| S:1171 E:1175 ||| MD
be  ||| S:1175 E:1178 ||| VB
part  ||| S:1178 E:1183 ||| NN
of  ||| S:1183 E:1186 ||| IN
this  ||| S:1186 E:1191 ||| DT
evolution  ||| S:1191 E:1201 ||| NN
process ||| S:1201 E:1208 ||| NN
,  ||| S:1208 E:1210 ||| ,
these  ||| S:1210 E:1216 ||| DT
polymorphisms  ||| S:1216 E:1230 ||| NNS
do  ||| S:1230 E:1233 ||| VBP
not  ||| S:1233 E:1237 ||| RB
affect  ||| S:1237 E:1244 ||| VB
HIV  ||| S:1244 E:1248 ||| JJ
susceptibility  ||| S:1248 E:1263 ||| NN
in  ||| S:1263 E:1266 ||| IN
the  ||| S:1266 E:1270 ||| DT
absence  ||| S:1270 E:1278 ||| NN
of  ||| S:1278 E:1281 ||| IN
primary  ||| S:1281 E:1289 ||| JJ
mutations ||| S:1289 E:1298 ||| NNS
.  ||| S:1298 E:1300 ||| .
Therefore ||| S:1300 E:1309 ||| RB
,  ||| S:1309 E:1311 ||| ,
all  ||| S:1311 E:1315 ||| DT
HIV-1  ||| S:1315 E:1321 ||| NNP
subtypes  ||| S:1321 E:1330 ||| NN
and  ||| S:1330 E:1334 ||| CC
groups ||| S:1334 E:1340 ||| NNS
,  ||| S:1340 E:1342 ||| ,
together  ||| S:1342 E:1351 ||| RB
with  ||| S:1351 E:1356 ||| IN
HIV-2 ||| S:1356 E:1361 ||| NNP
,  ||| S:1361 E:1363 ||| ,
are  ||| S:1363 E:1367 ||| VBP
naturally  ||| S:1367 E:1377 ||| RB
susceptible  ||| S:1377 E:1389 ||| JJ
to  ||| S:1389 E:1392 ||| TO
raltegravir ||| S:1392 E:1403 ||| VB
.  ||| S:1403 E:1405 ||| .
Finally ||| S:1405 E:1412 ||| RB
,  ||| S:1412 E:1414 ||| ,
because  ||| S:1414 E:1422 ||| IN
interaction  ||| S:1422 E:1434 ||| NN
of  ||| S:1434 E:1437 ||| IN
integrase  ||| S:1437 E:1447 ||| JJ
strand  ||| S:1447 E:1454 ||| JJ
transfer  ||| S:1454 E:1463 ||| NN
inhibitors  ||| S:1463 E:1474 ||| NN
with  ||| S:1474 E:1479 ||| IN
the  ||| S:1479 E:1483 ||| DT
HIV  ||| S:1483 E:1487 ||| NNP
integrase  ||| S:1487 E:1497 ||| VBD
active  ||| S:1497 E:1504 ||| JJ
site  ||| S:1504 E:1509 ||| NN
is  ||| S:1509 E:1512 ||| VBZ
comparable  ||| S:1512 E:1523 ||| JJ
from  ||| S:1523 E:1528 ||| IN
one  ||| S:1528 E:1532 ||| CD
compound  ||| S:1532 E:1541 ||| NN
to  ||| S:1541 E:1544 ||| TO
another ||| S:1544 E:1551 ||| DT
,  ||| S:1551 E:1553 ||| ,
raltegravir-resistant  ||| S:1553 E:1575 ||| JJ
viruses  ||| S:1575 E:1583 ||| NNS
express  ||| S:1583 E:1591 ||| VBP
significant  ||| S:1591 E:1603 ||| JJ
cross  ||| S:1603 E:1609 ||| NN
resistance  ||| S:1609 E:1620 ||| NN
to  ||| S:1620 E:1623 ||| TO
most  ||| S:1623 E:1628 ||| RBS
other  ||| S:1628 E:1634 ||| JJ
compounds  ||| S:1634 E:1644 ||| NN
of  ||| S:1644 E:1647 ||| IN
this  ||| S:1647 E:1652 ||| DT
new  ||| S:1652 E:1656 ||| JJ
class  ||| S:1656 E:1662 ||| NN
of  ||| S:1662 E:1665 ||| IN
antiretroviral  ||| S:1665 E:1680 ||| JJ
drugs ||| S:1680 E:1685 ||| NNS
.  ||| S:1685 E:1687 ||| .
